Enterprise Value
1.354B
Cash
405.9M
Avg Qtr Burn
-60.02M
Short % of Float
13.99%
Insider Ownership
6.80%
Institutional Own.
88.93%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REC-2282 Details Neurofibromatosis Type 2-mutated meningiomas | Phase 2/3 Data readout | |
REC-4881 Details Familial Adenomatous Polyposis | Phase 2 Data readout | |
REC-994 Details Cerebral cavernous malformation | Phase 2 Data readout | |
REC-3964 Details Clostridium difficile Colitis | Phase 2 Initiation | |
REC-4881 Details Cancer | Phase 2 Initiation | |
REC-3599 Details GM2 gangliosidosis | Failed Discontinued |